536 related articles for article (PubMed ID: 34739062)
21. Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA
Zhang SS; Ou SI
Lung Cancer (Auckl); 2022; 13():23-31. PubMed ID: 35506019
[TBL] [Abstract][Full Text] [Related]
22. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
[TBL] [Abstract][Full Text] [Related]
23. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
Cho JH; Lim SH; An HJ; Kim KH; Park KU; Kang EJ; Choi YH; Ahn MS; Lee MH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Clin Oncol; 2020 Feb; 38(5):488-495. PubMed ID: 31825714
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
Passaro A; Mok TSK; Attili I; Wu YL; Tsuboi M; de Marinis F; Peters S
JAMA Oncol; 2023 Aug; 9(8):1124-1131. PubMed ID: 37166792
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
[TBL] [Abstract][Full Text] [Related]
26. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
27. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
[TBL] [Abstract][Full Text] [Related]
28. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.
Majem M; Goldman JW; John T; Grohe C; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Li S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Atagi S; Zeng L; Kulkarni D; Medic N; Tsuboi M; Herbst RS; Wu YL
Clin Cancer Res; 2022 Jun; 28(11):2286-2296. PubMed ID: 35012927
[TBL] [Abstract][Full Text] [Related]
29. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
Kodama H; Wakuda K; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
Invest New Drugs; 2021 Apr; 39(2):571-577. PubMed ID: 32955628
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
31. Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
Nakao A; Hiranuma O; Uchino J; Sakaguchi C; Kita T; Hiraoka N; Ishizuka T; Kubota Y; Kawasaki M; Goto Y; Imai H; Hattori N; Nakatomi K; Uramoto H; Uryu K; Fukuda M; Uchida Y; Yokoyama T; Akai M; Mio T; Nagashima S; Chihara Y; Tamiya N; Kaneko Y; Mouri T; Yamada T; Yoshimura K; Fujita M; Takayama K
Oncologist; 2019 May; 24(5):593-e170. PubMed ID: 30651400
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Kelly K; Altorki NK; Eberhardt WE; O'Brien ME; Spigel DR; Crinò L; Tsai CM; Kim JH; Cho EK; Hoffman PC; Orlov SV; Serwatowski P; Wang J; Foley MA; Horan JD; Shepherd FA
J Clin Oncol; 2015 Dec; 33(34):4007-14. PubMed ID: 26324372
[TBL] [Abstract][Full Text] [Related]
33. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study.
Xing L; Pan Y; Shi Y; Shu Y; Feng J; Li W; Cao L; Wang L; Gu W; Song Y; Xing P; Liu Y; Gao W; Cui J; Hu N; Li R; Bao H; Shao Y; Yu J
Clin Cancer Res; 2020 Dec; 26(23):6168-6175. PubMed ID: 32817079
[TBL] [Abstract][Full Text] [Related]
35. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.
Cortellini A; Leonetti A; Catino A; Pizzutillo P; Ricciuti B; De Giglio A; Chiari R; Bordi P; Santini D; Giusti R; De Tursi M; Brocco D; Zoratto F; Rastelli F; Citarella F; Russano M; Filetti M; Marchetti P; Berardi R; Torniai M; Cortinovis D; Sala E; Maggioni C; Follador A; Macerelli M; Nigro O; Tuzi A; Iacono D; Migliorino MR; Banna G; Porzio G; Cannita K; Ferrara MG; Bria E; Galetta D; Ficorella C; Tiseo M
Clin Transl Oncol; 2020 Jun; 22(6):844-851. PubMed ID: 31392645
[TBL] [Abstract][Full Text] [Related]
36. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study.
Schmid S; Klingbiel D; Aeppli S; Britschgi C; Gautschi O; Pless M; Rothschild S; Wannesson L; Janthur W; Foerbs D; Demmer I; Jochum W; Früh M
Lung Cancer; 2019 Apr; 130():149-155. PubMed ID: 30885336
[TBL] [Abstract][Full Text] [Related]
37. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.
John T; Grohé C; Goldman JW; Shepherd FA; de Marinis F; Kato T; Wang Q; Su WC; Choi JH; Sriuranpong V; Melotti B; Fidler MJ; Chen J; Albayaty M; Stachowiak M; Taggart S; Wu YL; Tsuboi M; Herbst RS; Majem M
J Thorac Oncol; 2023 Sep; 18(9):1209-1221. PubMed ID: 37236398
[TBL] [Abstract][Full Text] [Related]
38. The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to Patients.
Maione P; Salvi R; Gridelli C
Curr Oncol; 2024 Feb; 31(2):987-997. PubMed ID: 38392068
[TBL] [Abstract][Full Text] [Related]
39. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
40. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
Fang W; Huang Y; Hong S; Zhang Z; Wang M; Gan J; Wang W; Guo H; Wang K; Zhang L
BMC Cancer; 2019 Jun; 19(1):595. PubMed ID: 31208370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]